Characteristics of the 54 Patients Included in the Trial at Time of Study Entry
| Variable . | Group A 375 mg/m2 (n = 28) . | Group B 500 mg/m2 (n = 26) . |
|---|---|---|
| Histology at diagnosis (REAL classification) | ||
| DLCL | 17 (61%) | 13 (50%) |
| MCL | 4 (14%) | 9 (35%) |
| FL | 1 (4%) | — |
| NOS | 6 (21%) | 4 (15%) |
| Mean time from diagnosis to study (SD) | 2.2 (2.37) | 1.6 (1.46) |
| Prior lymphoma history | ||
| First relapse | 8 (29%) | 9 (35%) |
| Second relapse | 4 (14%) | 1 (4%) |
| Primary refractory | 4 (14%) | 5 (19%) |
| PD after PR1 | 7 (25%) | 7 (27%) |
| Untreated | 5 (18%) | 4 (15%) |
| Prior ABMT | 6 (21%) | 3 (12%) |
| Median time from ABMT to study (mo) | 5 | 26 |
| Median age at study entry (range) | 62.5 (20-83) | 65 (32-86) |
| Karnofsky performance status | ||
| 90-100 | 16 (57%) | 13 (50%) |
| 70-80 | 12 (43%) | 13 (50%) |
| Median measurable tumor area in cm2 (range) | 25.4 (2-120) | 33 (5-374) |
| Variable . | Group A 375 mg/m2 (n = 28) . | Group B 500 mg/m2 (n = 26) . |
|---|---|---|
| Histology at diagnosis (REAL classification) | ||
| DLCL | 17 (61%) | 13 (50%) |
| MCL | 4 (14%) | 9 (35%) |
| FL | 1 (4%) | — |
| NOS | 6 (21%) | 4 (15%) |
| Mean time from diagnosis to study (SD) | 2.2 (2.37) | 1.6 (1.46) |
| Prior lymphoma history | ||
| First relapse | 8 (29%) | 9 (35%) |
| Second relapse | 4 (14%) | 1 (4%) |
| Primary refractory | 4 (14%) | 5 (19%) |
| PD after PR1 | 7 (25%) | 7 (27%) |
| Untreated | 5 (18%) | 4 (15%) |
| Prior ABMT | 6 (21%) | 3 (12%) |
| Median time from ABMT to study (mo) | 5 | 26 |
| Median age at study entry (range) | 62.5 (20-83) | 65 (32-86) |
| Karnofsky performance status | ||
| 90-100 | 16 (57%) | 13 (50%) |
| 70-80 | 12 (43%) | 13 (50%) |
| Median measurable tumor area in cm2 (range) | 25.4 (2-120) | 33 (5-374) |
Abbreviation: NOS, not otherwise specified.